Aug 26, 2020 / 12:10PM GMT
Jeffrey R. Baxter - VBI Vaccines Inc. - President, CEO & Director
Good morning, everyone, and thank you for joining us on this call today. We are delighted to share with you today the positive preclinical data from VBI-2900, our prophylactic coronavirus vaccine program, which enabled us to select 2 optimal candidates to take into an adaptive Phase I/II clinical study expected to begin around year-end 2020, subject to regulatory approvals.
I would refer you to the press release we issued this morning for more details on forward disclaimers regarding forward-looking statements, which are also outlined here on the slide. For additional corporate information and detail, I refer you to our SEC and our Canadian filings.
In March of this year, we announced a collaboration with the National Research Council of Canada to develop a vaccine program to address the coronavirus pandemic that has continued to have significant public health, economic and societal consequence. As part of this collaboration, a series of 3 preclinical mouse studies were initiated in the second quarter of 2020 to enable
VBI Vaccines Inc. - Special Call Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers